Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 11/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAG | P20916 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991802 | 0.91 | SELE (0.38) | SELEALDH1A1THRBMAGMAPK1 | |
| SCHEMBL24489383 | 0.87 | SELE (0.39) | SELEALDH1A1THRBMAGMAPK1 | |
| SCHEMBL21206319 | 0.84 | SELE (0.40) | SELEALDH1A1THRBMAG | |
| SCHEMBL21992388 | 0.83 | SELE (0.39) | SELEALDH1A1THRBMAG | |
| SCHEMBL24489397 | 0.80 | SELE (0.41) | SELEALDH1A1THRB | |
| SCHEMBL24489408 | 0.79 | SELE (0.43) | SELE | |
| SCHEMBL24489201 | 0.79 | SELE (0.52) | SELEMAGMAPK1 | |
| SCHEMBL19491871 | 0.76 | SELE (0.49) | SELEALDH1A1THRBMAPK1 | |
| SCHEMBL25446620 | 0.75 | SELE (0.48) | SELEALDH1A1THRBMAPK1SMN1; SMN2 | |
| SCHEMBL24489376 | 0.73 | SELE (0.42) | SELEALDH1A1THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | SELE, SELPLG, SELP | SELE 1/4885ALDH1A1 371/4885THRB 1735/4885 |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SELE 1/4885ALDH1A1 636/4885THRB 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.